Stereotaxis, Inc. designs, manufactures and markets robotic magnetic navigation systems for use in a hospital's interventional surgical suite to enhance the treatment of arrhythmias and coronary artery disease. The company is headquartered in St. Louis, Missouri and currently employs 130 full-time employees. The company went IPO on 2004-08-12. The Company’s robotic technology, Robotic Magnetic Navigation, fundamentally transforms endovascular interventions using precise computer-controlled magnetic fields to directly control the tip of flexible interventional catheters or devices. Its primary products include the Genesis RMN System, the Odyssey Solution, and other related devices. The firm also offers its customers the Stereotaxis Imaging Model S X-ray System and other accessory devices. The Genesis RMN System is designed to enable physicians to complete more complex interventional procedures by providing image-guided delivery of catheters through the blood vessels and chambers of the heart to treatment sites. The Odyssey Solution consolidates lab information onto one large integrated display, enabling physicians to view and control all the key information in the operating room.